Clinical Trial Update: CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 1/Phase 2 clinical trial evaluating seviteronel, a CYP17 lyase and androgen receptor inhibitor, in breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Male Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Seviteronel (seviteronel)

Snippet

Sponsor: Innocrin Pharmaceutical | Conditions: Cancer of the Breast, Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED